相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
100.0%
暂无批准数据
- Avance Clinical, a global contract research organization, has acquired U.S.-based oncology specialist LumaBridge to strengthen its position in the largest and fastest-growing therapeutic area in global R&D. - The acquisition establishes Avance's global Oncology Center of Excellence and expands the company's U.S. footprint with enhanced medical, scientific, and regulatory expertise for complex cancer studies. - The combined organization will serve more than 50 biotechnology companies developing oncology therapies, offering an integrated pathway from Phase I studies in Australia and New Zealand through later-phase global programs. - LumaBridge brings experienced oncology leadership and proven capabilities in delivering complex cancer studies for global biotech and pharmaceutical clients across early and later phase clinical development.
- Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency. - As only the fourth surgeon to serve as ASCO president, Mittendorf aims to leverage her surgical oncology perspective to optimize cancer care teams and integrate artificial intelligence technologies into clinical practice. - ASCO's strategic priorities under her leadership will center on improving access to care, advancing the profession, and enhancing knowledge while addressing workforce well-being and supporting early-career professionals through mentorship programs.
